Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-09-23
2008-09-23
Shibuya, Mark L (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S579000, C514S646000, C514S649000
Reexamination Certificate
active
11784148
ABSTRACT:
Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.
REFERENCES:
patent: 3225095 (1965-12-01), Thiele et al.
patent: 4021485 (1977-05-01), Schromm et al.
patent: 6268533 (2001-07-01), Gao et al.
patent: 6362371 (2002-03-01), Moran et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6593497 (2003-07-01), Choi et al.
patent: 6883115 (2005-04-01), Sanada
patent: 7217738 (2007-05-01), Moran et al.
patent: 2004/0248985 (2004-12-01), Sterglades et al.
patent: 2005/0075271 (2005-04-01), Linsell et al.
patent: 2007/0155990 (2007-07-01), Sterglades et al.
patent: 10-152460 (1998-06-01), None
Barnes, “Current Therapies for Asthma:Promise and Limitations”, CHEST, 111/2, pp. 17S-28S (1997).
Boyle, “Beta-Adrenergic Agonists”, Clinical Obstetrics and Gynecology, vol. 38, No. 4, pp. 688-696 (1995).
Greening et al., “Added aalmeterol versus higher-dose corticosteroid in asthma pationts with symptoms on existing Inhaled corticosteroid”, The Lancet, vol. 344, pp. 219-224 (1994).
Jack et al., “The 1990 Lilly Prize Lecture: A way of looking at agonism and antogonism:Lessons from salbutamol, salmeterol and other β-adrenoceptor agonists”, Br. J. clin. Pharmac., 31, pp. 501-514 (1991).
Mahler et al., “Efficacy of Salmeterol Xinafoate in the Treatment of COPD”, CHEST, 115/4, pp. 957-965 (1999).
Hoffman et al., “Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists”, Chapter 10, pp. 199-216; and 2) GRAVES, “Agents That Cause Contraction or Relaxation of the Uterus”, Chapter 39, p. 939-949, both in Goodman & Gilman's The Pharmacological Basic of Therapeutics, Ninth Edition (1996).
Choi Seok-Ki
Moran Edmund J.
Hagenah Jeffrey A.
Saxon Roberta P.
Shibuya Mark L
Theravance Inc.
LandOfFree
β2-adrenergic receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β2-adrenergic receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β2-adrenergic receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3958528